United Therapeutics Corp. (UTHR-Q)
NASDAQ:UTHR
308.00
1.08
(0.35%) 1d
Financials
Technical Analysis
Buy, Sell or Hold?
Related posts
Nervous markets await Nvidia
This summary was created by AI, based on 7 opinions in the last 12 months.
United Therapeutics Corp. (UTHR) has garnered positive attention from analysts, with several reviews confirming its strong performance and recommending adjustments to stop-loss levels. The reviews illustrate a trend of upward momentum, with previous investment gains reported between 22.8% to 60.7%. Analysts emphasize the company's disciplined approach, suggesting that current holders should consider trailing stops to secure profits while maintaining exposure to further gains. Furthermore, United Therapeutics demonstrates solid fundamentals, including cash reserves and a diversified product portfolio in the pulmonary hypertension medication market, adding to its investment appeal. Overall, experts maintain a favorable outlook, focusing on disciplined investment strategies to further enhance returns.
With cash reserves growing, debt being reduced and shares bought back, we again reiterate UTHR as a TOP PICK. The maker of pulmonary hypertension medications is well diversified among multiple products allowing margins to continue to grow. It trades at 12x earnings, under 2x book value and supports an 18% ROE. We recommend trailing up the stop (from $210) to $219, looking to achieve $292 -- upside potential of 21%. Yield 0%
(Analysts’ price target is $292.25)We again reiterate UTHR as a TOP PICK. Recently reported earnings beat analyst expectations as the company established all time high revenues. It is bullish on its hypertension medication. It trades at 13x earnings, 2x book and supports a 17% ROE. We like that cash reserves continue to grow based on solid operating cash flows. We continue to recommend a stop-loss at $210, looking to achieve $287 -- upside potential of 19%. Yield 0%
(Analysts’ price target is $286.96)We reiterate UTHR as a TOP PICK. When earnings are released next week, it is expected that revenues are up over 11%. It trades at 13x earnings and 2x book. Cash reserves have been growing, while debt is retired. We recommend trailing up the stop (from $190) to $210 at this time, looking to achieve $285 - upside potential of 25%. Yield 0%
(Analysts’ price target is $284.60)The company markets pulmonary hypertension treatment drugs. Recently reported earnings rose 117% on the year, beating estimates by 18%. Cash reserves are growing. The company trades at 12x earnings, under 2x book and supports a ROE of 17%. We recommend placing a stop-loss at $190, looking to achieve $284 -- upside potential of 28%. Yield 0%
(Analysts’ price target is $284.60)United Therapeutic (UTHR-Q) or Allergan (AGN-N)? This is a tough one because they are 2 very different companies. Allergan is a much larger company and more broadly-based, however, this one is a very fine company. Its primary drug therapy is dealing with pulmonary disease. The risk of owning this is that one drug represents a high percentage of their total revenue.
A good company. ROC has been improving, and has been very high. Back in 2008, it had a 4% ROC. Including the trailing 4 quarters, he now shows a 35% ROC, so he knows the company is doing everything right. Remember that when you have that high return, it can turn over really fast, but for now it is good.
(A Top Pick Dec 19/12. Up 115.38%.) Involved in a very specialized area, pulmonary arterial hypertension, which is high blood pressure in the lungs. The big spike in the stock price came as a result of FDA approval of an oral application for one of their drugs. They are quickly establishing themselves as the “go to” drug maker in this critical area where a lot of people are at risk.
(A Top Pick Dec 19/12. Up 81.38%.) Bio-pharmas are interesting because they have got a pipeline that is very exciting with new drugs coming on that are biology-based as opposed to chemical-based. Have always been extremely expensive, but this one isn’t. Trading at about 14-15 times next years earnings. There has to be a continuation of the acceptance of the existing product, but what he is really hoping for is an expansion of their product offering. They have 3 main drugs that they get most of their revenues off of. He’d like to see that at 6 or 12.
- «
- ‹
- 1
- ›
- »
United Therapeutics Corp.(UTHR-Q) Rating
Ranking : 4 out of 5
Bullish - Buy Signals / Votes : 6
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 6
Total Signals / Votes : 12
United Therapeutics Corp.(UTHR-Q) Frequently Asked Questions
What is United Therapeutics Corp. stock symbol?
United Therapeutics Corp. is a American stock, trading under the symbol UTHR-Q on the NASDAQ (UTHR). It is usually referred to as NASDAQ:UTHR or UTHR-Q
Is United Therapeutics Corp. a buy or a sell?
In the last year, 12 stock analysts published opinions about UTHR-Q. 6 analysts recommended to BUY the stock. 6 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for United Therapeutics Corp..
Is United Therapeutics Corp. a good investment or a top pick?
United Therapeutics Corp. was recommended as a Top Pick by on . Read the latest stock experts ratings for United Therapeutics Corp..
Why is United Therapeutics Corp. stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is United Therapeutics Corp. worth watching?
12 stock analysts on Stockchase covered United Therapeutics Corp. In the last year. It is a trending stock that is worth watching.
What is United Therapeutics Corp. stock price?
On 2025-05-08, United Therapeutics Corp. (UTHR-Q) stock closed at a price of $308.
Our PAST TOP PICK with UTHR has triggered its stop at $349. To remain disciplined, we recommend covering the position at this time. This will result in a net investment gain of 51%, when combined with our previous guidance.